Boston Scientific Corporation $BSX Shares Bought by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 106.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,805 shares of the medical equipment provider’s stock after acquiring an additional 62,204 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Boston Scientific were worth $12,651,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in BSX. 1248 Management LLC acquired a new position in shares of Boston Scientific during the first quarter worth about $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific during the 1st quarter worth approximately $27,000. Sound Income Strategies LLC lifted its position in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares in the last quarter. Princeton Global Asset Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific in the second quarter valued at approximately $37,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research note on Friday, October 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a report on Thursday, October 23rd. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Wells Fargo & Company lifted their target price on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Barclays increased their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $123.77.

Insider Buying and Selling

In related news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 175,782 shares of company stock valued at $17,742,314 over the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX opened at $97.06 on Thursday. The company has a market capitalization of $143.88 billion, a P/E ratio of 51.90, a PEG ratio of 2.02 and a beta of 0.58. The company has a 50-day moving average of $99.25 and a 200-day moving average of $102.47. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the firm earned $0.63 earnings per share. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.